Regional Business Development
Regional Director, Latin America
US Business Development Lead
Richard Barker's 30 year career in life sciences has included senior roles in biopharmaceuticals, diagnostics and medical informatics, and has spanned the commercial, public and charity sectors in Europe and the US. This career equips him as a leader in the better translation of medical innovation, specifically in precision medicine, and he founded New Medicine Partners for this purpose in 2016. He is a Visiting Professor of Medical Innovation at the University of Oxford, where he founded the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI). He chairs the Health Innovation Network and Genomic Medicine Centre in South London, and International Health Partners; he is also a board member of Celgene Corporation, Image Analysis Group and Kvatchii.
Past roles include Director General of the Association of the British Pharmaceutical Industry, Chief Executive of Chiron Diagnostics and General Manager of IBM's worldwide healthcare business.
Olga is an experienced consultant in Intellectual Property, investment and innovation management, and technology translation with specialisation in advanced engineering, medical devices, and precision medicine technologies. Olga holds positions as Senior Consultant at Oxentia (formerly Oxford University Innovations’ consulting arm) and at McGrigor Group, a global M&A advisory firm in health insurance and medical products and services, and as Associate Partner at Ruffena Capital, a London-based corporate finance advisory firm specialising in private equity investments in SMEs. Olga owns a boutique advisory firm focused on technology scouting and valuation, and is a contributor on Science, Innovation and Technology for the Calvert Journal, an award-winning on-line briefing resource on modern Russia. Until recently, Olga collaborated with the Russian Development Institutes within Project 5-100 aimed to boost the global competitiveness of Russian universities. Olga holds a doctorate degree in Materials from the University of Oxford.
Nick is a co-founder and CEO of Accunea Ltd, a medical device company with real time diagnostic monitoring products for patients with AKI. He also serves as a Strategic and Commercial Advisor for Capital Cell, a life sciences crowdfunding organisation based in the UK and Spain.
Nick has a PhD in Microbial Genetics from University of Warwick followed by post graduate research (genomics/biotechnology) at Harvard (DFCI, 1995) and Oxford (Biochemistry, 2000). At Oxford, the research in Professor Sir Ed Southern’s laboratory led to the creation of the spin out company Oxford Gene Technology Limited. Nick went on to secure a fellowship in technology transfer at the University of Warwick and then to Manchester as a business consultant to UMIC, mentoring entrepreneurs and commercial development of the bioincubator. This was followed by heading up the business group at Warwick HRI (2008) and the creation of Warwick Enterprise Park for provision of incubation facilities. Nick held several senior level positions as Scientist, CEO, NED, investor and Chairman in several start up enterprises such as the Oxford University start-up Oxagen (Human Genetics, 2003) Novolytics (antimicrobial therapeutics, 2010), BioMimox (peptide aptamers, 2014), Arcamis (business consulting, 2010), and has served as the Director of Business Development at OBN (2012). Nick has raised significant public, private, VC and business angel funding (Beer and Partners, 2013) for several businesses (multiple £M) and was a coach for the Growth Accelerator programme. More recently Nick created the Molecular Diagnostics Centre within the John Radcliffe Hospital, Oxford, building self-sustainability models and international collaborations and partnerships. Nick also led the successful bid to become the Oxford Genomics Medicine Centre and the Director of the Programme. Nick is a current member of the Diagnostics Advisory Council in Oxfordshire; has advised on Genomics products for ThermoFisher; was a lecturer at MIB (Manchester) in genomics; and graduated (2016) with a PGDiP in Strategy and Innovation from the Said Business School in Oxford.
Elin Haf Davies is a paediatric and rare disease drug development specialist, with over 20 years of clinical, academic and regulatory expertise. Elin holds a doctorate degree from University College London. Following six years at the European Medicine Agency and extensive collaboration with academic and pharmaceutical partners Elin has in-depth understanding of adaptive pathways, and their potential to address high unmet needs. To address the need of real-time, long-term patient monitoring Elin founded Aparito Digital Health, a company that utilises innovative wearables and real-time analytics to provide meaningful patient generated data to clinicians, regulators and reimbursement agencies.
Charles is a Senior Advisor for Public Health England and acts in a variety of external facing positions with government and other agencies. He leads dementia and risk reduction initiatives for Public Health England, and was recently appointed as director of antibiotic prescribing as part of the Antimicrobial Resistance Initiative.
Charles has extensive experience of health care in a variety of senior positions in both primary and secondary care as well as PCTs and Health Authorities, assuming the role of Chairman of National Association of Primary Care, part of the NHS confederation, from 1st January 2012 until September 2014 where he was at the heart of the recent health and social care reforms. Previously as Medical director and PEC chair, he was intimately involved in the running and setting up of the Kingston Clinical Commissioning Group providing services to over 195,000 patients, 29 practices and over a 130 GPs.
He has extensive experience of working at senior levels both internationally, in both Europe and the Americas. He is internationally active advising both Governments and international organisations. He also has experience of military medicine until recently acting as Director of Medicine and Clinical Governance for the British Armed Forces in Germany. In January 2016, he assumed the role of Visiting Scholar at the world health innovation network at the Odette school of business, University of Windsor, Ontario Canada.
Andrew Krentz is an academic clinician and researcher with more than three decades of experience in metabolic, endocrine and cardiovascular disorders. His current positions include: Visiting Professor, Institute of Cardiovascular & Metabolic Research, University of Reading, UK; Academic Fellow, Centre for the Advancement of Sustainable Medical Innovation (CASMI), UK; Senior Research Fellow, ProSciento, San Diego, USA; Editor-in-Chief Cardiovascular Endocrinology & Metabolism, London, UK; Clinical Instructor, University of California San Diego, USA; Council Member Royal Society of Medicine Section of Lipids, Metabolism & Vascular Risk, London, UK. Andrew is accredited as a clinical specialist by the European Society for Hypertension. He is an affiliate member of the Faculty of Pharmaceutical Medicine at the Royal College of Physicians of London.
Previous positions include: Professor of Endocrinology & Metabolism and Director of the Institute of Translational Medicine, Clore Life Sciences laboratory, University of Buckingham, UK; Visiting Professor of Medicine, Institute of Diabetes for Older People, Beds & Herts Postgraduate Medical School, University of Bedfordshire, UK; Lead Consultant Physician in Diabetes & Endocrinology, Southampton University Hospitals, UK; Senior Clinical Lecturer, University of Southampton, UK; British Heart Foundation International Research Fellow, University of California San Diego, USA; Research Fellow, Division of Endocrinology & Metabolism, University of New Mexico School of Medicine, Albuquerque, USA.
Andrew’s textbook publications include: Insulin Resistance: A Clinical Handbook (2002); The Metabolic Syndrome & Cardiovascular Disease (2007); Drug Treatment of Type 2 Diabetes (2012); Translational Research Methods for Diabetes, Obesity & Cardiometabolic Drug Development: A Focus on Early Phase Clinical Studies (2015).
Alan’s career in the health sciences comprises basic research, investment management/capital markets, strategic consultancy and executive operations. Starting his career as research chemist at Merck in the New Lead Discovery Department, after his academic work he joined management consultancy McKinsey serving leading companies globally. He subsequently became Director at Commerzbank Asset Management ($140bn AUM) in London and Frankfurt in charge of global healthcare investments as well as overall industrial investment research. He co-founded, took public and was first CEO and CFO of Chiral Quest, a life sciences company in the area of chiral pharmaceuticals. He is currently Director at Fitzroy Partners in London developing new life sciences ventures in emerging areas.
Dr Roth earned his BA (Hons) from Cornell University, PhD in organic chemistry from Columbia University, and Postdoctoral Fellowship in medicinal chemistry from the University of Oxford. He is a Guest Professor at Oxford University, the University of Cologne (Germany), the University of Tianjin (China), and the US Military Academy, West Point (USA).
Tomaz works on socioeconomic and research frameworks to support development in high-potential, resource constrained countries. His experience encompasses work with NGOs, research centres and industry. He is also actively involved in the setup and technology transfer operations at the National Institute of Chemistry, Slovenia and serves as a COO at an investment platform. Apart from that he is currently focused on establishing an international link between the Cambridge (UK) and Slovenian healthtech landscapes.
Tomaz holds a MPhil degree in Bioscience Enterprise from the University of Cambridge and hachieved finalists’ round of the Cambridge Entrepreneur of the Year and the Gap Summit Leaders of Tomorrow competitions. Prior education in Multimedia Communications enables him to approach digital and technology healthcare-related topics. He has also supplemented his degree education with trainings in the field of start-up creation and investments proposals and nurturing entrepreneurial mindset in research settings.
Dr A. Ray Chaudhuri is a serial entrepreneur, angel investor and operator. He currently advises life-science and tech startups in the US, Europe and Asia and is the digital health and healthcare expert for two venture funds. His entrepreneurial and advisory interests cover US, India and China. Most recently Ray has worked in several established Healthcare AI companies. Prior to that he was the CEO of a digital health company in Silicon Valley which he grew from concept to a partnership with a large Pharma. Previously, he advised the growth of a precision medicine company in New Orleans, from 12 to 700 employees and $3M to $150M in less than 24 months and also assisted in the raise of $55M. Earlier, he was the CEO of a vaccine and therapeutic antibody company focused on rare diseases. In the past, he was brought in to turn around a 10 year old biotech and became the CFO and completed approx. $400M of deals with several top large pharmas. He started his career as a Venture Capitalist in a $120M venture fund based in Maryland. His background includes finance, healthcare AI, synthetic biology, cell and gene therapy, oncology, infectious disease and stem cell biology. Ray has a PhD in immunology and regenerative medicine and an MBA in Finance.